2. Academic Validation
  3. NLRP3 inflammasome-driven hemophagocytic lymphohistiocytosis occurs independent of IL-1β and IL-18 and is targetable by BET inhibitors

NLRP3 inflammasome-driven hemophagocytic lymphohistiocytosis occurs independent of IL-1β and IL-18 and is targetable by BET inhibitors

  • Sci Adv. 2025 Jul 11;11(28):eadv0079. doi: 10.1126/sciadv.adv0079.
Farzaneh Shojaee 1 2,  Esmaeel Azadian 1 2,  Min Xian Wong 1 2 3,  Xiuquan Ma 1 2,  James Rickard 4,  Jiyi Pang 1 2,  Catherine Hall 1 2,  Andrew J Kueh 1 2 5 6,  Seth L Masters 1 2 7 8,  Inmaculada Rioja 9,  Rab K Prinjha 10,  Marcel Doerflinger 1 2,  Kate E Lawlor 1 2 7 8,  Maryam Rashidi 1 2,  James E Vince 1 2
Affiliations

Affiliations

  • 1 The Walter and Eliza Hall Institute of Medical Research, Parkville 3052, Australia.
  • 2 Department of Medical Biology, University of Melbourne, Parkville 3010, Australia.
  • 3 Department of Biological Sciences, National University of Singapore, Singapore 117558, Singapore.
  • 4 Dorevitch Pathology, Heidelberg 3084, Australia.
  • 5 Olivia Newton-John Cancer and Wellness Centre, Austin Health, Heidelberg 3084, Australia.
  • 6 School of Cancer Medicine, La Trobe University, Heidelberg 3084, Australia.
  • 7 Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton 3168, Australia.
  • 8 Department of Molecular and Translational Science, Monash University, Clayton 3168, Australia.
  • 9 BicycleTx Limited, Portway Building, Granta Park, Cambridge CB21 6GS, UK.
  • 10 Curve Therapeutics, Delta House, Enterprise Road, Southampton Science Park, Southampton SO16 7NS, UK.
PMID: 40632844 DOI: 10.1126/sciadv.adv0079
Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a potentially fatal cytokine storm syndrome. Its high mortality rate reflects limited therapeutic options and a poor understanding of disease-causing signaling. We show that the NLRP3 inflammasome is responsible for increased mortality in a model of secondary HLH (sHLH). Unexpectedly, neither deletion of the NLRP3-activated pyroptotic effector GSDMD nor combined deletion of the inflammasome-activated cytokines interleukin-1β (IL-1β) and IL-18 conferred strong protection from sHLH. Instead, co-deletion of GSDMD and caspase-8-activated GSDME limited sHLH-driven lethality, demonstrating redundancy in the pyroptotic machinery required to induce sHLH. We also found that bromodomain and extraterminal domain (BET) inhibitors prevent NLRP3-driven Pyroptosis, which acted by blocking inflammasome priming. BET inhibitors prevented increased NLRP3 levels in diseased tissue, limited the production of sHLH-associated IL-1β, interferon-γ, and tumor necrosis factor, and protected from sHLH pathogenesis. These findings suggest that targeting NLRP3 could limit sHLH and identify clinically relevant bromodomain-selective BET inhibitors capable of eliminating NLRP3-driven Pyroptosis and the sHLH cytokine storm.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z